OBSTETRICS & GYNECOLOGY
cervical canal and endometrium revealed a high microbial seeding rate (Chlamidia trachomatis -15.7%, M.genitalium -21.6%, Gardnerella vaginalis -46.2%, Candida albicans -14.5%, Trichomonas vaginalis - 7.2%).

The listed pathogens were found in 65.2% of patients in the vagina and epithelium of the cervical canal and 57.3% of patients in the endometrium.

Conclusion. By inference, for the prevention of recurrence of genital endometriosis before the appointment of the traditional therapy of endometriosis, it is necessary to carry out rational antibacterial therapy, taking into account the sensitivity of the flora to antibiotics.

Halanina Juliia, Mykhailova Julia
Kharkiv National Medical University
Department of Obstetrics and Gynaecology No.1
Kharkiv, Ukraine
Scientific advisor: ass. prof. Sharashidze K.Z.

OPERATIVE TREATMENT OF THE TRUE FUSED PLACENTA IN THE AREA OF THE OLD POSTOPERATIVE SCAR

Introduction. The true fused placenta is a very serious, life-threatening pathology of pregnancy, which is relatively rare (1 case per 3000-5000 births), can lead to massive bleeding and pregnancy complications, often with repeated birth, usually after cesarean section. A study conducted in 2006 by R. Silver and co-authors revealed a significant increase in the risk of fused placenta, correlating to the number of uterine scars: with 1 scar - 3%, 2 - 11%, 3 - 40%; 4 - 61% and 5 - 67%. According to the study of S.L. Clark and co-authors if there is one uterine scar, the risk of an increase in the placenta is 24%, and if there is 4 or more - 67%. According to statistics, the fused placenta in complete placental presentation of women who do not have a caesarean section in the history of delivery, is found in 2.5%, with a uterine scar - in 34.5%. Fused placenta is a colossal problem in obstetrics due to the risk of massive obstetric bleeding, as a result of which abnormal placentation is one of the main causes of maternal mortality.

Purpose of the study. Determination of the significance of treatment of the true fused placenta in the area of the old postoperative scar of women after a cesarean section.

Results. The patient was routinely admitted for operative delivery to the perinatal center. In anamnesis there is delivery in 2013 by cesarean section in urgent order, due to the primary weakness of labor. The second pregnancy II proceeded without complications. Considering the uterine scar, operative delivery is routinely medically indicated: laparotomy, cesarean section in the lower uterine segment according to Derfler. Intraoperatively: the placenta was located on the front wall of the uterus, attention was attracted by the bleeding, the true fused placenta in the postoperative scar (placenta increta). Cicatrectomy of the old postoperative scar with placenta increment was performed; the scar was sent for histologic study. After excision, the bleeding stopped. The uterus is closed up with a double-row vikril suture.

Conclusions. Fused placenta it is a severe condition that requires timely diagnosis and treatment. In this clinical case, the fused placenta in the area of the old postoperative scar has become a favorable factor for the preservation of the reproductive function of this woman. Based on the above data, the parturition of this group of patients should be carried out in medical institutions that provide the third level of care with adequate resources and the presence of highly qualified specialists. With the growing number of placenta increments, there is an urgent need to improve the methods of diagnosis and treatment.

Hladka Iryna
Kharkiv National Medical University
Department of Obstetrics, Gynecology and Pediatric Gynecology
Kharkiv, Ukraine
Scientific advisor: prof. Tuchkina I.A.

BLOODLESS COLPOPOIESIS

Introduction. A conservative method of treatment is colpoelongation according to B.F. Sherstnev. According to this method, an artificial vagina is formed by stretching the mucous vestibule of the vagina and deepening the “fossa” existing or formed during the
SILENT MYOCARDIAL ISCHEMIA ASSOCIATED WITH LONG TERM RISK OF HEART FAILURE & SUDDEN CARDIAC DEATH ................................................................. 70
OREL NADIA, HOLOVIA HANNA, LIAKH ALINA ............................................................................................ 71
FUNCTIONAL DISORDERS OF THE GASTROINTESTINAL TRACT AND THEIR PREVALENCE BETWEEN THE STUDENTS OF KNMU ........................................................................................................................................................................... 71
PANCHENKO DANIL, BIDA DARIA ............................................................................................................. 73
CLINICAL MANIFESTATIONS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA ........................................... 73
PYLOV DANYLO ......................................................................................................................................... 74
THE RELATIONSHIP BETWEEN VASPIN, TNF-A LEVELS AND THE PARAMETERS OF CARBOHYDRATE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ................................................................................................................................. 74
RYZOVA DARYNA, Litvinova KATERYNA, KHIMICH TATIANA .................................................................... 75
BRUTON'S DISEASE .................................................................................................................................... 75
SHAPARENKO OLEandr ................................................................................................................................ 77
CHANGES OF THE END DIASTOLIC SIZE OF A MYOCARDIUM OF THE LEFT VENTRICLE ACCORDING TO AN ECHOCARDIOGRAPHY IN PATIENTS WITH HYPERTENSION IN COMBINATION WITH OBESITY DEPENDING ON IRISIN LEVEL ........................................................................................................................................... 77
SHCHOLOK TETIANA ..................................................................................................................................... 78
INDIVIDUALIZED ANTIOXIDANT THERAPY INCREASES EFFEVTIVENESS OF THE BASIS ISCHEMIC HEART DISEASE TREATMENT .................................................................................................................................................. 78
STOYAN ANNA ............................................................................................................................................... 79
DETERMINATION OF THE PREVALENCE OF HELICOBACTER PYLORI INFECTIONS AMONG MEDICAL STUDENTS ON THE BACKGROUND OF MEASURING METABOLIC INDICATORS ......................................................................................................................... 79
STOIANOVA JULIA, MARKEVYCH MYKYTA .................................................................................................. 80
DIAGNOSTIC ESSAYS OF CLINICAL MASKS OF AUTOIMMUNE HEPATITIS .................................................... 80
SYPALO ANNA, HASSAN ELMIR ................................................................................................................... 81
THE ESTIMATION OF RELATION BETWEEN SORTILIN AND LIPID METABOLISM INDICATORS IN PATIENTS WITH CORONARY HEART DISEASE AND DIABETES MELLITUS TYPE 2 .............................................................................................................................. 81
ZHURAVLOVA MARINA .............................................................................................................................. 83
CHANGES OF CALPROTECTIN, PARAMETERS OF IMMUNE INFLAMMATION WITH PARAMETERS OF LIPID AND CARBON EXCHANGE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ........................................................................................................... 83
ZHURAVLOVA ANNA, GANIZADE NIHAD ...................................................................................................... 84
ABDOMINAL OBESITY AS A PREDICTOR OF GERD DEVELOPMENT ................................................................ 84
ABEKA KOAMAPAH ................................................................................................................................. 87
CONTROVERSY OF THE MANAGEMENT OF CERVICAL LOW-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (LSIL) ................................................................................................................................. 87
AMANDA AMOO-MENSAB, WILLIAM KODZO ASAMANY, ROMANENKO ANNA...................................................... 88
PRE-ECLAMPSIA AS A RISK FACTOR FOR DIABETES ....................................................................................... 88
ANASTASIIA PIATYHOR ................................................................................................................................... 89
DIFFERENT METHODS OF THERAPY OF ABNORMAL UTERINE BLEEDING IN WOMEN OF REPRODUCTIVE AGE ........................................................................................................................................................................... 89
ANHELINA SIKIRNITSKA .............................................................................................................................. 90
THE CONTEMPORARY METHODS OF EARLY SEXUAL MATURATION DIAGNOSTICS ........................................... 90
ANN MAKOVETSka ......................................................................................................................................... 92
COMPARISON OF THE CLINICAL MANIFESTATIONS OF CERVICAL INFLAMMATION DISEASES ASSOCIATED WITH AND WITHOUT HUMAN PAPILLOMA VIRUS (HPV) INFECTION WITH THE RESULTS OF LABORATORY EVALUATION OF VAGINAL MICROBIOCENOSIS .............................................................................................................................. 92
ARALOVA VIKTORIYA ............................................................................................................................... 93
IMMUNOLOGICAL RISK FACTORS IN THE PREDICTION OF PREMATURE ABORTION ........................................... 93
AVAZOVA AFINA ............................................................................................................................................. 95
A CLINICAL CASE OF ISTMIC-CERVICAL INSUFFICIENCY IN THE 2ND TRIMESTER .............................................. 95
CHEKHUNOVA ANASTASIA ............................................................................................................................ 96
MICROBIOCENOSIS OF THE VAGINA, EPITHELIUM OF THE CERVICAL CANAL AND ENDOMETRIUM IN PATIENTS WITH GENITAL ENDOMETRIOSIS ........................................................................................................................................... 96
HALANINA JULIJA, MYKHAILOVA JULIJA ......................................................................................................... 97
OPERATIVE TREATMENT OF THE TRUE FUSED PLACENTA IN THE AREA OF THE OLD POSTOPERATIVE SCAR .................................................................................................................................................. 97
HLADKA IRyna .............................................................................................................................................. 98
BLOODLESS COLPOPOIESIS ......................................................................................................................... 98
KATERYNA BOROHOLOVA, ANASTASIiA NAHORNA ..................................................................................... 100
PATIENTS WITH PERINATAL LOSS IN THE FIRST TRIMESTER OF PREGNANCY .................................................. 100
KONOVAL ANZHELA ..................................................................................................................................... 101
COMBINED TREATMENT OF MICROBIAL ASSOCIATIONS IN SALPINGOOPHORITIS ............................................. 101
KUPCHYK KHRYSTYNA ................................................................................................................................... 102
VACCINE PREVENTION OF CERVICAL CANCER .......................................................................................... 102